BUSINESS UPDATE: Celadon Pharmaceuticals Plc (CEL) Announces its successful MHRA inspection for GMP

Celadon Pharmaceuticals Plc has completed the necessary submissions and inspections with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the good manufacturing practices (GMP) manufacturing of its cannabis-based active pharmaceutical ingredient (API).
The company received positive results from independent third-party testing of its API and expects to receive registration from the MHRA for the GMP manufacturing of its cannabis API in Q1 2023. This will make Celadon one of a limited number of GMP approved pharmaceutical cannabis facilities in the world.
Read More: https://www.londonstockexchange.com/news-article/CEL/update-on-gmp-registration-by-mhra/15768839
OTHER POSTS
-
PRESS: Britain could be getting high on the benefits of a full-scale medical cannabis industry
-
PRESS: British Pain Society features Celadon Pharmaceuticals Plc
-
PRESS: Celadon Pharmaceutical’s CEO Jim Short featured discussing new MHRA framework
-
PRESS: Inside huge top-secret legal cannabis facility hidden away in Birmingham that is the size of three football pitches